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Caloric restriction blocks neuropathology and
motor deﬁcits in Machado–Joseph disease mouse
models through SIRT1 pathway
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Machado–Joseph disease (MJD) is a neurodegenerative disorder characterized by an
abnormal expansion of the CAG triplet in the ATXN3 gene, translating into a polyglutamine
tract within the ataxin-3 protein. The available treatments only ameliorate symptomatology
and do not block disease progression. In this study we ﬁnd that caloric restriction dramatically
rescues the motor incoordination, imbalance and the associated neuropathology in transgenic
MJD mice. We further show that caloric restriction rescues SIRT1 levels in transgenic MJD
mice, whereas silencing SIRT1 is sufﬁcient to prevent the beneﬁcial effects on MJD pathology.
In addition, the re-establishment of SIRT1 levels in MJD mouse model, through the gene
delivery approach, signiﬁcantly ameliorates neuropathology, reducing neuroinﬂammation and
activating autophagy. Furthermore, the pharmacological activation of SIRT1 with resveratrol
signiﬁcantly reduces motor incoordination of MJD mice. The pharmacological SIRT1
activation could provide important beneﬁts to treat MJD patients.
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T
he polyglutamine (polyQ) diseases are a group of genetic
neurodegenerative pathologies triggered by an over-
repetition of the trinucleotide cytosine–adenine–guanine
within the open reading frame of different genes and encoding
long polyQ tracts in the respective proteins. The translated
proteins tend to misfold and aggregate causing dysfunction and
degeneration of speciﬁc neuronal subpopulations.
Machado–Joseph disease (MJD), also known as spinocerebellar
ataxia type 3 (ref. 1) is one of these polyglutamine diseases, whose
mutation is mapped to chromosome 14q32.1 (ref. 2). Despite
rare, it is the most common autosomal dominantly inherited
ataxia and reaches high prevalence in certain regions of Portugal,
in particular in the islands of Azores3,4. The disorder has its onset
at adult age and involves neurodegeneration within cerebellar
systems, substantia nigra, cranial nerve motor nuclei5,6 and the
striatum7,8, resulting in clinical hallmarks that include motor
incoordination, postural instability, dysarthria and dysphagia
among other symptoms9. Neurodegeneration is associated with
accumulation of the polyglutamine-expanded ataxin-3 (stretch
over 55 repeats)10 in the cells11,12. To this contributes the
cleavage of the mutated protein in toxic fragments, mediated by
calpains13–15 and the inefﬁcient activation of autophagy to clear
the mutant ataxin-3 (refs 16,17). There is no treatment to prevent
or slow the progression of MJD and only symptomatic treatments
for the disease currently exist.
Caloric restriction (CR) is a dietary regimen involving
consumption of fewer calories than usual but containing all the
essential nutrients, without malnutrition. Since 1935 it is known
that CR increases longevity in rats18 and over the last years it has
been proved that CR extends lifespan in a wide spectrum of
species19. Emerging data show that this effect is conserved in
non-human primates, although some controversy subsists20–22.
The role of CR in neuroprotection was ﬁrst revealed in 1990,
when Park et al.23 showed that CR attenuated the age-related loss
of spinal ganglion neurons in mice23 and its application in
neurodegenerative disorders has been explored from that time
on24–26. How CR exerts its beneﬁcial effects has been the object of
several hypotheses and its knowledge may contribute to open new
therapeutic strategies for neurodegenerative diseases and other
age-related diseases.
Sir2 or silent information regulator 2 was found in yeast and its
mammalian orthologues are known as sirtuins (SIRTs). SIRTs are
NADþ -dependent deacetylases found to slow ageing in yeast and
higher organisms, including mammals27–29. Their activity is
required for effects of CR in many organisms30. In mammals,
seven SIRTs have been identiﬁed, namely SIRT1–7. Each SIRT
has a speciﬁc cellular localization and function. SIRT1 is the
most closed orthologue of Sir2, as Sir2 is a NADþ -dependent
deacetylase that is mainly located in the nucleus31 and is so far
the most studied member in this family. Moreover, SIRT1 is
activated by some compounds, such as, resveratrol32. It has
been reported that SIRT1 plays a neuroprotective role in
Huntington’s disease33,34, and spinal and bulbar muscular
atrophy35, both polyglutamine diseases. Nevertheless, until
now the protective role of SIRT1 in other polyglutamine
diseases, namely spinocerebellar ataxias, had not been
investigated.
In the present study we provide compelling evidence that CR
not only robustly mitigates the neuropathology but also rescues
motor impairments in mouse models of MJD. The knowledge of
the main mechanism(s) underlying these effects is crucial to
develop a new therapeutic strategy to be applied in humans.
We show that CR alleviation of MJD is mediated by SIRT1,
highlighting the beneﬁts of increasing SIRT1 expression or
activity to alleviate this and potentially other spinocerebellar
ataxias.
Results
CR drastically alleviates motor deﬁcits in MJD mice. Previously,
Torashima et al.36 showed that the transgenic (Tg) MJD mouse
model used in this study exhibits a remarkable cerebellar atrophy
and a severe loss of motor coordination and balance, since at least
the third week of age36. In the present study, the motor
coordination and balance of Tg MJD mice maintained with ad
libitum (AL) diet or with CR diet were evaluated by beam walking
test, stationary and accelerated rotarod tests, pole test and
swimming test. We started the CR regimen in 6-week-old mice,
thus in a postsymptomatic stage of the disease. To follow the
effects of CR during the progressive stages of the disease,
behavioural outcomes were measured every 3 weeks until the end
of the study.
Six weeks after the beginning of CR diet, Tg MJD mice showed
a clear improvement in motor coordination and balance,
evaluated by beam walking test, which reached signiﬁcance for
the 6 and 9mm, round and square beams at this time point
(Supplementary Fig. 1). At 9 weeks’ time point, 15-week-old,
calorie-restricted Tg MJD mice showed a robust improvement of
motor coordination and balance, compared with AL mice
(Fig. 1b).
To further assess motor coordination and balance, stationary
and accelerated rotarod tests were performed. In stationary
rotarod, Tg mice maintained in the AL diet quickly fell off the
stationary rotarod, whereas calorie-restricted Tg mice exhibited
an impressive improvement of performance (4.5 times) from the
sixth week onwards (Fig. 1c; t¼ 6 weeks; Tg-AL: 33.7±7.0 s
versus Tg-CR: 132.7±29.9 s). Similar results were obtained with
the accelerated rotarod (Fig. 1d; Tg-AL: 25.3±3.0 s versus Tg-CR:
51.4±4.2 s), which persisted along the experimental time course
in both protocols.
This improvement in motor coordination and balance was
additionally investigated with the pole test. Tg MJD mice in the
control group showed a remarkably prolonged t-turn, compared
with the calorie-restricted group, from the sixth week onwards
(Fig. 1e; t¼ 6 weeks; Tg-AL: 28.7±9.4 s versus Tg-CR:
10.0±2.4 s). Moreover, calorie-restricted Tg mice descended the
vertical beam faster than mice in the AL diet and this difference
was statistically different since the third week (Fig. 1f; t¼ 3 weeks;
Tg-AL: 20.6±1.4 s versus Tg-CR: 15.0±1.5 s) and was
maintained along the experimental time.
Using the swimming test, we observed that calorie-restricted
MJD Tg mice, since the third week, swam faster and showed less
difﬁculties to reach the platform, in comparison with the control
group (Fig. 1g; t¼ 3 weeks; Tg-AL: 30.3±1.3 s versus Tg-CR:
18.7±2.4 s). Importantly, at 6 and 9 weeks after the beginning of
the study, performance of calorie-restricted Tg MJD mice did not
differ from the performance of wild-type (WT) mice, suggesting
that a complete rescue of the phenotype occurred (Fig. 1g; t¼ 6
weeks; Tg-CR: 10.8±1.1 s versus (WT-CR: 6.3±0.8 s or versus
n¼ 5 WT-AL: 6.3±0.9 s)).
Furthermore, gait was studied by analysis of footprint patterns.
Nine weeks after the beginning of the CR diet, Tg mice in the CR
diet showed a rescue of the affected footprint overlap (Fig. 1h;
t¼ 9 weeks; Tg-AL: 1.12±0.05 cm versus Tg-CR: 0.57±0.06 cm;
WT-AL: 0.39±0.028 cm versus Tg-CR: 0.57±0.06 cm; P40.05).
A similar outcome was registered on the analysis of stride length.
Calorie-restricted Tg MJD mice showed a consistently longer
stride length in comparison with the control group (Fig. 1i;
Tg-AL: 5.6±0.15 cm versus Tg-CR: 6.09±0.14 cm). These results
show a signiﬁcant improvement in the affected gait of Tg MJD
mice with CR diet.
Finally, horizontal locomotor activity was evaluated by the
open-ﬁeld test. Calorie-restricted Tg MJD mice completely
reverted the typical hypoactivity of this model (Fig. 1j), travelling
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consistently longer distances than the AL mice (Fig. 1j; t¼ 9
weeks; Tg-AL: 45.15±2.40m versus Tg-CR: 56.02±3.11m),
with a higher mean velocity (Fig. 1k; t¼ 9 weeks; Tg-AL:
1.972.0±0.14 cm s 1 versus Tg-CR: 2.36±0.12 cm s 1), in both
cases reaching the values observed for WT mice. Altogether, these
results show that CR improves locomotor activity.
Importantly, no differences were found for WT mice submitted
to CR or AL diets in any behaviour test. This ﬁnding suggests that
CR animals do not perform better in these tests simply because
they are leaner. Altogether, these data demonstrate that 9 weeks
of CR robustly reduces the severe motor deﬁcits in a
postsymptomatic Tg mouse model of MJD.
CR ameliorates neuropathology of MJD mice. Next, we wanted
to investigate whether motor improvements, triggered by CR,
correlate with histopathological changes in the cerebellum.
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Figure 2 | Nine weeks of CR prevents cerebellar neuropathology in Tg MJD mice. (a) Cresyl violet-stained sections demonstrate the thickness of
molecular layer (ML) and granular layer (GL) of lobule V of cerebellum in 15-week-old littermate WTand Tg MJD mice in AL or CR diet, quantiﬁed in b and
c. Scale bar, 50mm. (d) Quantiﬁcation of cerebellar volume showed a signiﬁcantly higher cerebellar volume in calorie-restricted mice. (e) Analysis of the
number of mutant ataxin-3 inclusions in the cerebellar Purkinje cells of Tg MJD mice. The total number of aggregates in Purkinje cells is signiﬁcantly lower
in calorie-restricted mice, in comparison with AL mice. (f) Relative levels of the soluble form of mutant ataxin-3 normalized with b-actin were signiﬁcantly
decreased in Tg mice in the CR diet. Data represent mean±s.e.m.; NS P40.05 and *Po0.05 compared with Tg-AL. (b–d). One-way analysis of variance
with Bonferroni’s post-hoc test. (e,f) Unpaired Student’s t-test. WT-AL n¼ 3; WT-CR n¼4; Tg-AL n¼4; Tg-CR n¼4.
Figure 1 | CR alleviates balance and motor coordination impairments and ameliorates gait and locomotor activity in a Tg MJD mouse model.
(a) Representative study design; 6-week-old Tg and WT littermate mice were divided in two groups: AL group (AL) and calorie-restricted group (CR).
Every 3 weeks, behavioural tests were performed, until animals were 15 weeks old. (b) Beam walking test demonstrating an amelioration of the motor
performance of calorie-restricted mice, 9 weeks after the beginning of CR diet. (c,d) Tg MJD mice in CR diet had better performance in constant velocity
(5 r.p.m.) and accelerated (from 4 to 40 r.p.m.) rotarod, compared with Tg MJD AL mice. (e,f) Vertical pole test. Since the sixth week, calorie-restricted Tg
MJD mice turned downwards easier than the Tg mice in the AL diet (e) and descended the beam with less difﬁculties (f). (g) Swimming test performance.
Since the sixth week, Tg mice exhibited a rescue of the common improper performance in the swimming pool. (h,i) Quantitative analysis of the footprint
patterns. Calorie-restricted mice had a higher stride length and a more perfect footprint overlap and their performance is signiﬁcantly closer to WT
performance, 9 weeks after the beginning of CR diet. (j,k) Open-ﬁeld test. Calorie-restricted Tg MJD mice travelled the same distance and with the same
mean velocity than WTmice. Calorie-restricted mice had a higher stride length and a more perfect footprint overlap, and their performance is signiﬁcantly
closer to WT performance, 9 weeks after the beginning of CR diet. Data represent mean±s.e.m.; NS P40.05, *Po0.05, **Po0.01 and ***Po0.001
compared with Tg-AL. (b–g) Two-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test. (h–k) One-way ANOVA with Bonferroni’s post-hoc
test. WT-AL n¼ 5; WT-CR n¼ 7; Tg-AL n¼6; Tg-CR n¼ 7. See also Supplementary Fig. 1.
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Tg MJD mice used in this study present severe cerebellar atrophy
and Purkinje cells are speciﬁcally affected36. Representative
images of cerebellar lobule V conﬁrm the generalized cerebellar
atrophy in Tg MJD mice (Fig. 2a). We evaluated neuropathology
at the last time point (9 weeks after the beginning of CR) when we
observed the most prominent CR effects in motor behaviour.
In agreement with the behavioural data, 15 weeks old calorie-
restricted Tg MJD mice exhibited signiﬁcantly larger layers
thickness in comparison with AL mice (Fig. 2b; molecular layer:
Tg-AL: 55.1±3.0 mm and Tg-CR: 70.3±1.5 mm; Fig. 2c; granular
layer: Tg-AL: 69.5±0.7 mm versus Tg-CR: 89.9±3.2 mm),
which suggests prevention of neurodegeneration. In contrast, no
difference was found in layer thickness within the two groups
of WT mice (Fig. 2b; molecular layer: WT-AL: 122.9±3.1 mm;
WT-CR: 114.3±6.2 mm; Fig. 2c; granular layer: WT-AL:
123.8±6.7 mm versus WT-CR: 117.9±2.5 mm). Cerebellar
volume was also evaluated and calorie-restricted Tg MJD mice
had a signiﬁcantly larger cerebellar volume in comparison with
the AL Tg group (Fig. 2d; Tg-AL: 10.1±0.1mm3 versus Tg-CR:
12.6±0.4mm3). Again, there was no difference between the two
groups of WT mice (Fig. 2d; n¼ 3 WT-AL: 37.4±1.2mm3 versus
n¼ 4 WT-CR: 36.9±1.5mm3).
The polyQ expansion in mutant ataxin-3 leads to the
formation of intranuclear inclusions, one of the main hallmarks
of MJD12,37. Therefore, we investigated whether beneﬁcial effects
of CR in motor abnormalities are related with changes in the
number of mutant ataxin-3 aggregates in the cerebellum.
The number of aggregates in Purkinje cells of the cerebellum
in calorie-restricted Tg mice was reduced around 30% in
comparison with the AL Tg mice (Fig. 2e; Tg-AL: 4680±393
versus Tg-CR: 3214±271) and the levels of soluble mutant ataxin
(Fig. 2f).
Altogether, these results demonstrate that CR prevents
cerebellar neurodegeneration in MJD mice, while it
simultaneously decreases the levels of mutant ataxin-3.
CR reverts abnormal decrease of SIRT1 levels. As increases in
SIRT1 levels and activity are intrinsically related to the effects on
lifespan and neuroprotection mediated by CR38,39, we evaluated
the messenger RNA and protein levels of SIRT1 in the cerebellum
of 15-week-old WT versus AL or calorie-restricted MJD Tg mice.
A dramatic decrease of 58.4±8.3% in mRNA levels and of
38.5±8.8% in protein levels of SIRT1 in Tg MJD mice, in
comparison with WT littermate (Fig. 3a,b), was observed. The
same results were observed in human ﬁbroblasts of MJD patients
in comparison with healthy patients (data not shown). On CR,
SIRT1 mRNA and protein levels were completely re-established
to the levels observed in the non-diseased mice (Fig. 3a,b). As
expected, CR also induced the activation of SIRT1, evaluated by
the decrease in acetylated levels of the SIRT1 substrate, Forkhead
box protein O1 (Supplementary Fig. 2).
Overall, these results suggest that SIRT1 expression is
compromised in the cerebellum of Tg MJD mice and CR can
revert this defect, reinstating normal SIRT1 levels.
SIRT1 overexpression ameliorates MJD neuropathology.
Previously, we showed that CR robustly mitigated MJD pheno-
type and reverted the compromised cerebellar levels of SIRT1 in
mice. We then investigated whether lentiviral overexpression of
SIRT1 would be sufﬁcient to mimic the effects of CR and mediate
similar alleviation of MJD pathology. For this purpose, we took
advantage of a genetic mouse model of MJD generated by loca-
lized lentiviral-mediated expression of mutant ataxin-3 in the
striatum, another affected brain region in MJD7,13. This model is
particularly useful, as it allows a precise quantiﬁcation of
neuropathology regarding loss of the Dopamine- and cyclic
AMP-regulated phosphoprotein 32 (DARPP-32) marker and
number of ataxin-3 aggregates in speciﬁc regions of interest.
Therefore, in 5-week-old WT mice we stereotaxically co-injected
in the left hemisphere lentiviral vectors encoding for mutant
ataxin-3 and an inactive SIRT1 mutant—H363Y—as control
(control hemisphere), whereas in the right hemisphere we
co-injected lentiviral vectors encoding for mutant ataxin 3 and
for SIRT1 (Fig. 4a). SIRT1 overexpression was speciﬁcally located
at the striatum and, as expected, induced a decrease in the
deacetylation levels of SIRT1 substrate—Forkhead box protein
O1—in the striatum (Fig. 4b,c).
Insoluble aggregates of ataxin-3, despite the unclear role in the
pathology, are a hallmark of the disease that can be used as a
surrogate marker. By immunohistochemistry (Fig. 4d,e) and by
western blotting (Fig. 4f), we observed that SIRT1 overexpression
induced a 60.9±4.8% decrease in the total number of aggregates
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(Fig. 4e; non-treated: 136,960±26,808 versus SIRT1 50,480±
5,960) and a signiﬁcant decrease in the aggregated and soluble
forms of mutant ataxin-3 (Fig. 4f). Interestingly, the B34 and
B26 kDa toxic fragments, resulting from processing of mutant
ataxin-3 (ref. 13), were also decreased in the hemisphere where
SIRT1 was overexpressed, indicating an interference of SIRT1 in
the process of formation or degradation of these fragments. No
changes were observed regarding the mRNA levels of mutant
ataxin-3 (Fig. 4g). Altogether, these results suggest that SIRT1
overexpression decreases accumulation and aggregation of
mutant ataxin-3 in intranuclear inclusions and decreases the
levels of toxic fragments, contributing to the decrease of mutant
ataxin-3 toxicity.
In the control hemisphere DARPP-32 immunoreactivity
decreased with a depleted staining volume of 0.78±0.10mm3,
whereas in the contralateral hemisphere SIRT1 overexpression
reduced the volume depletion of DARPP-32 by 52%
(0.41±0.09mm3; Fig. 4h,i), clearly demonstrating its neuro-
protective activity.
Furthermore, bright-ﬁeld images showed a small condensation
of the internal capsule of the striatum, triggered by neuronal
dysfunction induced by mutant ataxin-3, in the control
hemisphere, which was not observed in the hemisphere where
SIRT1 was overexpressed (Fig. 4j, left). Importantly, SIRT1
overexpression reduced by 42.0±10.7% the number of pyknotic
nuclei (Fig. 4k). These data suggest that SIRT1 prevents cell injury
and striatal degeneration triggered by mutant ataxin-3.
SIRT1 overexpression decreases MJD neuroinﬂammation.
To explore the mechanism(s) by which SIRT1 overexpression
produced beneﬁcial effects on MJD mouse models, we
investigated whether SIRT1 interferes with the characteristic
neuroinﬂammation observed in the lentiviral MJD mouse
model7,40.
In non-treated hemispheres, we observed a local glial ﬁbrillary
acidic protein immunoreactivity increase, suggestive of astrocytic
activation. SIRT1 overexpression reduced glial ﬁbrillary acidic
protein immunoreactivity (Fig. 5a–c). In addition, in the non-
treated hemisphere, a strong immunoreactivity for the microglial
marker Iba-1 was observed, revealing microglial recruitment,
which was robustly and signiﬁcantly reduced in the hemisphere
where we overexpressed SIRT1 (Fig. 5d,e). These results suggest
that SIRT1 overexpression prevents reactive gliosis associated
with MJD.
Furthermore, we analysed the changes in the mRNA levels of
inﬂammatory cytokines, namely interleukin (IL)-1b, IL-6, tumour
necrosis factor-a (TNF-a) and IL-10. We found a strong and
signiﬁcant decrease in the mRNA levels of pro-inﬂammatory
cytokines (IL-1b, IL-6 and TNF-a) in the hemisphere, where we
overexpressed SIRT1 relative to the non-treated hemisphere
(Fig. 5f–h). Interestingly, the levels of one anti-inﬂammatory
cytokine, IL-10, were not different between non-treated and
SIRT1-overexpressing striata (Fig. 5i). These results suggest that
SIRT1 has a speciﬁc downregulating effect over pro-inﬂammatory
cytokines, but does not have effects on the anti-inﬂammatory
network.
Overall data indicate that, at least, one of the mechanisms
by which SIRT1 ameliorates neuropathology of MJD in
striatal lentiviral model of MJD is by the downregulation of
neuroinﬂammatory markers.
In vitro and in vivo SIRT1 overexpression activates autophagy.
SIRT1 deacetylase activity is important for autophagy activation
induced by starved conditions41. In addition, we previously
demonstrated that autophagy is compromised in MJD and its
activation can alleviate MJD16,17. Therefore, we hypothesized
that SIRT1 increases mutant ataxin-3 clearance by activating
autophagy.
First, to explore whether autophagy could be activated by CR,
we evaluated LC3BII and p62 protein levels in the cerebella of
15-week-old Tg animals fed during 9 weeks with a CR versus AL
diet. We observed a signiﬁcant increase in LC3BII levels and a
decrease in p62 levels in cerebella of MJD Tg mice fed with CR
diet, in comparison with MJD TgAL- fed animals (Supple-
mentary Fig. 3). Moreover, we evaluated the same parameters in
the striatum of the lentiviral model of MJD mice where SIRT1
was overexpressed in comparison with the overexpression of a
non-functional SIRT1 (H363Y). Interestingly, we also observed a
signiﬁcant increase in LC3BII and a decrease in p62 levels, in the
striatum where SIRT1 was overexpressed in comparison with
H363Y overexpression. These results suggest that in fact SIRT1
activates autophagy in MJD mice (Fig. 5j,k). To further assess
more precisely what SIRT1 does to autophagic ﬂux, we performed
an in vitro study, using Neuro2a cells expressing mutant ataxin-3
in the presence and absence of a lysosomal inhibitor—
chloroquine. Interestingly, in cells overexpressing SIRT1, we
observed an increase in LC3BII levels, in comparison with control
cells (Fig. 5l). To conﬁrm whether SIRT1 is activating autophagy,
we evaluated LC3BII levels in the presence of the lysosomal
degradation inhibitor (chloroquine 100mM) and again an
increase in LC3BII levels was observed, as compared with control
condition (Fig. 5l). Cells overexpressing SIRT1 also exhibited a
signiﬁcant decrease in p62 or sequestosome 1 (SQSTM1), in
comparison with control condition (Fig. 5m), which, as expected,
was prevented in the presence of chloroquine. In addition, SIRT1
overexpression induced a decrease of mutant ataxin-3, which was
prevented by chloroquine (Fig. 5n).
Furthermore, to better understand the direct effect of SIRT1 on
autophagy pathway and on MJD pathology, we performed
additional experiments using the same in vitro model of MJD
Figure 4 | SIRT1 overexpression reduces mutant ataxin-3 toxicity and neuronal dysfunction in a striatal lentiviral model of MJD. (a) Schematic
representation of the strategy used to create in vivo striatal lentiviral model of MJD and to overexpress SIRT1/H363Y. Five-week-old C57Bl/6J mice were
bilaterally injected with lentiviral vectors encoding for mutant ataxin-3. In the left hemisphere were co-injected lentiviral vectors encoding for H363Yand in
the right hemisphere for SIRT1. Four weeks after the surgery, mice were euthanized. (b) SIRT1 immunoreactivity in the striatum of animals of the striatal
lentiviral model of MJD co-injected with H363Yor SIRT1 versus a control animal. DAPI, blue, nuclei. Scale bar, 500mm. (c) Acetylated Forkhead box protein
O1 (FOXO1) levels are signiﬁcantly lower in the striata of lentiviral model of MJD when the active form of SIRT1 was overexpressed, in comparison with
control side where the inactive form of SIRT1 was overexpressed. (d) With an anti-ataxin-3 antibody (Ab 1H9), total number of mutant ataxin-3 inclusions
were counted and are quantiﬁed in e. Scale bar, 500mm. (f) Western blot analysis demonstrated that SIRT1 overexpression signiﬁcantly reduced several
toxic forms of mutant ataxin-3, namely aggregates, soluble form andB34 andB26 kDa fragments. (g) Quantitative reverse transcriptase–PCR analysis of
Atx3MUTmRNA. (h) DARPP-32 staining revealed a major loss of DARPP-32 immunoreactivity in the striatal hemisphere co-infected with mutant ataxin-3
and H363Y. Scale bar, 500mm. This was quantiﬁed in i as depleted volume of DARPP-32 staining. (j) Cresyl violet staining indicating pyknotic nuclei in both
hemispheres. A higher number of pyknotic nuclei were visible around the injection site area in the H363Y-transduced hemisphere. Scale bar, 500 mm
(brightﬁeld and left cresyl violet) and 50mm (right cresyl violet). This was quantiﬁed in k. Data represent mean±s.e.m. *Po0.05, **Po0.01 and
***Po0.001 compared with non-treated hemisphere. (c,e–g,i,k) Paired Student’s t-test. n¼4.
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that is suitable to address autophagy features—Neuro2a cells
expressing mutant ataxin-3. We generated a short hairpin RNA
(shRNA) targeting ATG5 in addition to the shRNA targeting
SIRT1. In the Neuro2a cell line expressing a mutated form of
ataxin-3, we genetically silenced SIRT1 or ATG5 in comparison
with a control shRNA. We evaluated by western blotting, the
protein levels of LC3BII and p62. As expected, we observed that
genetic silencing of ATG5 signiﬁcantly decreased the conversion
of LC3BI to LC3BII (Supplementary Fig. 4a) and induced an
accumulation of p62 (Supplementary Fig. 4b) and consequently
mutant ataxin-3 (Supplementary Fig. 4c). Similar results
were obtained on autophagy inhibition by SIRT1 knockdown,
indicating that SIRT1 inhibition causes autophagic ﬂux
disruption. To further clarify the mechanism through which
SIRT1 deacetylating activity stimulates autophagy and clears
mutant ataxin-3, in cells expressing mutant ataxin-3, we
genetically silenced ATG5 (or not) and overexpressed SIRT1 or
the non-functional SIRT1—H363Y. Interestingly, we made the
following observations: (1) as expected, when autophagy is not
disrupted, SIRT1 activates autophagy, demonstrated by the
increase in LCBII levels and the decrease in p62; (2) SIRT1
induces mutant ataxin-3 clearance and to do this its deacetylase
activity is crucial, because its inactive form (H363Y) had no
effects; (3) if autophagy is disrupted (here promoted by ATG5
genetic silencing), SIRT1 is not able to reduce mutant ataxin-3
levels, indicating that it is by activating autophagy that SIRT1
mediates the clearance of mutant ataxin-3 (Supplementary Fig. 5).
This study indicates that in fact SIRT1 plays an important role in
ataxin-3 clearance through the participation on autophagy,
because the reduction of mutant ataxin-3 promoted by SIRT1 is
reverted when ATG5 is genetically silenced.
Altogether, these results suggest that SIRT1 activates
autophagy and this could result on mutant ataxin-3 clearance
and consequently to the decrease in its levels.
CR alleviates MJD by increasing SIRT1 levels. To investigate
whether the mechanism of CR is mediated by SIRT1, we eval-
uated whether silencing SIRT1 would prevent the neuroprotective
effects of CR in the striatal lentiviral model of MJD. Thus,
we considered four conditions: (1) animals injected with vectors
encoding mutant ataxin-3 and given AL diet, (2) the same but
food restricted, (3) food restricted and co-injected in the left
hemisphere with lentiviral vectors encoding for mutant ataxin-3
and a control shRNA and (4) food restricted and co-injected in
the right hemisphere with lentiviral vectors encoding for mutant
ataxin-3 and for a shRNA targeting mouse SIRT1.
As expected, DARPP-32 volume depletion and the number of
mutant ataxin-3 inclusions were signiﬁcantly reduced in calorie-
restricted mice compared with AL mice (Fig. 6a,b; AL:
80,200±3,040 versus 53,720±10,190; P¼ 0.050; Fig. 6c,d; AL:
0.37±0.05mm3 versus CR: 0.22± 0.03mm3). Protein levels of
SIRT1 were also increased by 63.2±12.5% in the striatum of
calorie-restricted mice (Fig. 6e).
In contrast, silencing striatal SIRT1 (shSIRT1 CR) blocked the
beneﬁcial effects of CR as compared with control (shCNTL CR)
(Fig. 6f–j). In fact, in SIRT1-silenced mice CR did not change
the pathological striatal features induced by mutant ataxin-3,
such as the number of aggregates in the striatum (Fig. 6b,h;
AL: 80,200±3,040 versus shRNA SIRT1 CR: 94,830±15,810;
P40.05) neither DARPP-32 volume depletion (Fig. 6d,j;
AL: 0.37±0.05mm3 versus shRNA SIRT1 CR: 0.34±0.07mm3;
P40.05), completely reverting the neuropathology to the one
observed in AL mice.
Altogether, these results demonstrate that SIRT1 mediates the
robust neuroprotective effects of CR in MJD.
Resveratrol treatment improves motor behaviour in MJD mice.
In addition, we explored whether a pharmacological activator of
SIRT1—the resveratrol—could be an effective therapy for the
disease. We started the treatment with resveratrol in 6-week-old
Tg mice, in a postsymptomatic stage of the disease. The results
show that resveratrol decreases the motor deﬁcits and imbalance
of MJD mice observed in stationary and accelerated rotarod tests
(Fig. 7a,b), and also in beam-walking test (Fig. 7c). Moreover, in
Tg MJD mice we observed that resveratrol treatment was able to
re-establish SIRT1 mRNA levels (Fig. 7d), in a similar way as CR
did (Fig. 3a).
Altogether, these results suggest that resveratrol could be a
potential pharmacological therapy to treat MJD patients.
Discussion
In the present study we provide strong evidence demonstrating
that CR robustly alleviates the neuropathology in two MJD mouse
models (Tg and lentiviral MJD models) and rescues the motor
impairments by a mechanism involving the upregulation of
SIRT1, and consequent inhibition of neuroinﬂammation and
activation of autophagy.
The cerebellum is one of the brain regions where neuro-
pathology is most prominent in MJD and cerebellar damages
cause motor incoordination, explaining the disabling clinical
features of MJD5. The MJD Tg mice that we used in this study36
display a speciﬁc expression of the mutant ataxin-3 in Purkinje
Figure 5 | SIRT1 overexpression reduces MJD-associated neuroinﬂammation and activates autophagy. (a–e) Quantitative analysis of glial ﬁbrillary
acidic protein (GFAP) and ionized calcium binding adaptor molecule 1 (Iba-1) immunoreactivity at 4 weeks after the co-injection of the viral vectors in the
striatal lentiviral model of MJD. (a–c) SIRT1 decreased astrocytic activation induced by mutant ataxin-3, evidenced by the decrease in GFAP
immunoreactivity and by the reduction in GFAP protein levels, evaluated by western blotting in c. (d,e) SIRT1 reduced microglia recruitment triggered by
mutant ataxin-3, supported by the decrease of Iba-1 immunoreactivity, in comparison with the control hemisphere. Scale bar, 500mm in larger images and
100mm in smaller images. (f–i) mRNA levels of inﬂammatory cytokines were evaluated by quantitative reverse transcriptase–PCR. (f–h) mRNA levels of
pro-inﬂammatory IL-1b, IL-6 and TNF-a cytokines were signiﬁcantly decreased in the hemisphere where SIRT1 was overexpressed. (i) mRNA levels of
anti-inﬂammatory IL-10 cytokine were not changed with SIRT1 overexpression. (j,k) SIRT1 overexpression activates autophagic ﬂux in the striatum of
striatal lentiviral model of MJD. (j) SIRT1 overexpression induces an increase in LC3BII levels, in comparison with the overexpression of H363Y.
(k) SIRT1 overexpression reduces signiﬁcantly p62 levels, in comparison with the hemisphere where H363Y was overexpressed. (l–n) Neuro 2a cells were
co-infected with lentivirus encoding for mutant ataxin-3 and for H363Y (control condition) or co-infected with lentivirus encoding for mutant ataxin-3 and
for SIRT1. (l) SIRT1 overexpression in the presence or absence of an autophagic ﬂux inhibitor increased LC3BII levels. (m) In the absence of chloroquine,
p62 levels were increased and did not change in the presence of the lysosomal inhibitor. (n) Mutant ataxin-3 levels were reduced when SIRT1 was
overexpressed in the cells, in the absence of chloroquine. In the presence of chloroquine, the changes were not observed. Data represent mean±s.e.m.
*Po0.05 , **Po0.01 and ***Po0.001 compared with control. (b,e–k). Paired Student’s t-test. n¼4. (l–n) Two-way analysis of variance with Bonferroni’s
post-hoc test. n¼4. See also Supplementary Figs 3–5.
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Figure 6 | CR alleviates MJD neuropathology by the SIRT1 pathway in striatal lentiviral model of MJD. (a) Mutant ataxin-3 aggregates counting,
quantiﬁed in b, showed that CR decreased mutant ataxin-3 inclusions in the striatum. Scale bar, 500mm. (c) A higher DARPP-32 volume depletion,
quantiﬁed in d, was observed in animals in an AL diet, compared with calorie-restricted mice. Scale bar, 500 mm. (e) Immunoblotting demonstrating that
calorie-restricted mice have an increase in the protein levels of SIRT1 in striatum in comparison with AL mice. (f) Schematic representation of the study.
Five-week-old C57Bl/6J mice were stereotaxically injected in the striatum. In each hemisphere we injected lentiviral vectors encoding for mutant ataxin-3;
in the left hemisphere was co-injected lentiviral vectors encoding for the shRNA control and in the right hemisphere was co-injected lentiviral vectors
encoding for the shRNA targeting SIRT1. Four days after the surgeries, animals were divided in two groups. One group of mice was maintained in an AL diet
and the other was in a CR diet. (g) Mutant ataxin-3 inclusions counting showed that SIRT1 silencing prevented the decrease in the number of inclusions
induced by CR. This was quantiﬁed in h. Scale bar, 500mm. (i) DARPP-32 staining revealed that genetic silencing of SIRT1 in the striatal lentiviral model of
MJD induced a blockage of the beneﬁts of CR. This was quantiﬁed in j. Scale bar, 500mm. Data represent mean±s.e.m.; *Po0.05 and **Po0.01 compared
with control. (b,d,e) Unpaired Student’s t-test. n¼ 5. (h,j) Paired Student’s t-test. n¼ 5.
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cells of the cerebellar cortex. Mice of this MJD model exhibit
cerebellar atrophy and an early pronounced ataxic motor
behaviour. We started the study after the development of the
ataxic behaviour—in other words, in a postsymptomatic stage of
the disease. In the present work, we show, with several
behavioural tests, that CR strongly ameliorates the severe motor
deﬁcits of this Tg mouse model of MJD. Furthermore, in
comparison with the AL-fed MJD mice, we observed that CR also
decreases the neuropathology features of these mice, namely
mediating an amelioration of cerebellar atrophy, molecular and
granular layer thickness in the cerebellar cortex, while promoting
a signiﬁcant decrease in the aggregated and soluble forms of
mutant ataxin-3 in Purkinje cells and in the cerebellar tissue.
We suggest that the Purkinje cell preservation observed in
calorie-restricted MJD mice resulted from the decrease in mutant
ataxin-3 toxicity and this may explain the preserved larger
molecular and granular layers thickness in comparison with
AL-fed animals. Moreover, we also evaluated the effects in the
striatal lentiviral model of MJD. In this model of MJD, we
stereotaxically inject lentiviral vectors encoding for a mutated
form of ataxin-3 in the striatum of 5-week-old mice, inducing
neuropathology from the second week on, including striatal
mutant ataxin-3 inclusions, synaptic loss and astrogliosis3,6,7–9.
In the CR and in the SIRT1 lentiviral overexpression experiments
using this model of the disease, we started the treatments at an
early stage of the disease, namely before the development of the
aforementioned alterations, complementing the observations
made with the previous mouse model of the disease. Therefore,
using two complementary MJD mouse models, we observed
that CR and SIRT1 overexpression ameliorate the neuropathology
in two stages of the disease: postsymptomatic and at an
initial stage.
Some previous studies described beneﬁts of CR in neuro-
degenerative disorders such as Parkinson’s, Alzheimer’s and
Huntington’s diseases24–26. Speciﬁcally, Qin et al.26 demonstrated
that in Alzheimer’s disease, the neuroprotection mediated by CR
can be reproduced by manipulating cellular SIRT1 expression/
activity, highlighting the role of SIRT1 in the effects of CR26.
Another more recent study showed that CR induced the
expression of SIRT1 and pharmacological activation of SIRT1
replicated the effects of CR in a neurodegeneration mouse
model39. The increase in SIRT1 seems to be neuroprotective
and, thus, to ameliorate neuropathology in some diseases.
Interestingly, in the Tg mouse model of MJD used in the
present study we observed that SIRT1 protein levels were
decreased in the cerebellum, and that CR restored its levels,
ameliorating MJD neuropathology. Besides, we wanted to
investigate the potential beneﬁcial effects resulting from SIRT1
overexpression in the striatum of MJD mouse model, to clarify
the importance of SIRT1 in this mouse model of the disease. The
results show that SIRT1 overexpression signiﬁcantly reduced the
characteristic MJD neuropathology highlighting the role and
importance of SIRT1 in the disease.
The mechanism underlying the neuroprotective effects pro-
moted by CR is not fully understood. In fact, there is a myriad of
mechanisms described in which CR participates. It is described
that CR increases the levels of neurotrophic factors and of
stress-resistance proteins, such as heat shock protein 70, induces
changes in regulatory proteins, namely in FOXOs proteins,
and that these changes contribute to neuroprotection24,25,42.
To further explore whether SIRT1 is the major mediator of CR
beneﬁcial effects, we genetically silenced SIRT1 in the striatum of
AL versus calorie-restricted mice of the lentiviral model of MJD.
We found compelling evidence demonstrating that CR drives
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treated Tg MJD mice showed a signiﬁcant better performance in constant velocity (5 r.p.m.) and accelerated (from 4 to 40 r.p.m.) rotarods, since the
second week of treatment (eighth week after birth), compared with vehicle-treated Tg MJD mice. (c) Beam walking test with two square beams (18 or
9mm width) and two round beams (9 or 6mm diameter), demonstrating an amelioration of the motor performance promoted by resveratrol. (d) SIRT1
mRNA levels are decreased in Tg MJD animals (Tg-Vehicle) in comparison with WTmice (WT). SIRT1 mRNA levels are re-established with 8 weeks of daily
treatment with 10mg kg 1 body weight of resveratrol (Tg-Resveratrol). Data represent mean±s.e.m. (a–c) NS, nonsigniﬁcant; *Po0.05, **Po0.01 and
***Po0.001 compared with Tg vehicle-treated mice. Two-way analysis of variance (ANOVA) with Bonferroni’s post-hoc test. Unpaired Student’s t-test.
n¼ 8–9. (d) Data represent mean±s.e.m. NS. P40.05 and **Po0.01. Relative to WTmice. One-way ANOVA with Bonferroni’s post-hoc test. WT: n¼ 6;
Tg-Vehicle: n¼ 5; Tg-Resveratrol: n¼ 5.
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its beneﬁts mainly through the effects of SIRT1, due to the
absence of neuroprotection in mice where SIRT1 was genetically
silenced.
In recent times, we described that neuroinﬂammation and
reactive gliosis is a feature of MJD in the two genetic mouse
models of MJD that we used in this study40,43. Moreover,
it was previously suggested that neuroinﬂammation, at least in
part, underlies the neuroprotective action of CR and/or SIRT1
(ref. 44). Taking this information into account, we evaluated
neuroinﬂammatory markers in the affected brain region of MJD
mouse models after CR regimen and we observed in the striatum
of the lentiviral MJD mouse model a signiﬁcant decrease of gliosis
markers and mRNA levels of pro-inﬂammatory cytokines (IL-1b,
IL-6 and TNF-a), but no change on anti-inﬂammatory cytokine
levels (IL-10). As others showed that SIRT1 deacetylates and
inactivates nuclear factor-kB, a transcription factor that controls
the gene expression of pro-inﬂammatory cytokines genes such as
IL-1b, IL-6 and TNF-a (refs 45,46), our results suggest an effect of
SIRT1 on the pro-inﬂammatory network.
It was also described that SIRT1 can activate autophagy,
through the deacetylation and activation of important autophagy-
related proteins, namely Atg5, Atg7 and Atg8 (ref. 47). Moreover,
it was recently shown that SIRT1 plays a crucial role in
autophagy, contributing to nuclear LC3 deacetylation, driving
its transportation for the cytoplasm and the initiation of
autophagy under starvation conditions41. Accordingly, we
observed an activation of autophagy, triggered by SIRT1, which
was speciﬁcally mediated by its deacetylase activity, given the
absence of effects in the control condition (H363Y) where
deacetylase activity was not present. We also observed a decrease
in mutant ataxin-3 levels, suggesting that the reduction of
mutant ataxin-3 toxicity is associated to autophagy activation
and promotion of mutant ataxin-3 clearance. Thus, SIRT1 can
deacetylate important autophagic substrates, leading to autophagy
activation, mutant ataxin-3 clearance and a reduction in toxic
fragments, thereby ameliorating neurodegeneration. The
reduction in fragments described before could also be linked to
the activation of autophagy. In fact, the faster turnover of soluble
mutant ataxin-3 can contribute to the decrease in mutant ataxin-3
fragment levels. These results are in accordance to the absence of
changes in mutant ataxin-3 mRNA, which is suggestive of a
decrease of the different forms of ataxin-3 independently of
transcriptional alterations.
In conclusion, the present study shows that SIRT1 activation
strongly improves motor deﬁcits and neuropathology in mouse
models of MJD by SIRT1-mediated effects. Thus, a therapy based
on SIRT1 activation and increasing SIRT1 levels, as resveratrol, is
a promising approach for MJD therapy.
Methods
Animals and treatments. C57Bl/6 mice were obtained from Charles River, Spain,
and C57Bl/6-background Tg MJD mice and age-matched WT control mice were
previously described36,48; a colony of these Tg mice was established at the Centre
for Neuroscience and Cell Biology of the University of Coimbra. Mice were housed
under conventional 12-h light–dark cycle in a temperature-controlled room with
water provided AL and food restricted or AL, depending on the group of study.
Mice were fed with a standard AIN-93G diet. Since the sixth week after birth, in a
postsymptomatic stage of the disease, calorie-restricted mice were fed with an
amount of food equal to 90% of that consumed by mice in AL-fed corresponding
group in the ﬁrst period (10% of CR), 80% in the second period (20% of CR) and
70% from third period until the end of the study (30% of CR), without
malnutrition. In resveratrol study, 6-week-old animals were intraperitoneally
injected with vehicle or 10mg kg 1 of body weight of resveratrol in 25% dimethyl
sulfoxide in saline solution in a ﬁnal volume of 50–70 ml adjusted for the body
weight, daily during 8 weeks. The experiments were carried out in accordance with
the European Community directive (2010/63/EU) for the care and use of
laboratory animals. The researchers received adequate training (FELASA certiﬁed
course) and certiﬁcation to perform the experiments from Portuguese authorities
(Direc¸a˜o Geral de Veterina´ria).
Lentiviral vectors production. Lentiviral vectors encoding human mutant
ataxin 3 (LV-PGK-Atx-3 72Q), human SIRT1 (LV-PGK-SIRT1), H363Y
(LV-PGK-H363Y), negative shRNA (LV-PGK-EGFP-H1-shRNA CNTL) and
shRNA targeting mouse SIRT1 (LV-PGK-EGFP-H1-shRNA SIRT1) were
produced in HEK293T cell line with a four-plasmid system, as previously
described49. Lentiviral particles were re-suspended in 1% BSA in sterile PBS.
The viral particle content of batches was evaluated by assessing HIV-1 p24 antigen
levels by ELISA (Retro Tek, Gentaur, Paris, France). Concentrated viral stocks were
stored at  80 C until use.
Stereotaxic injection into the striatum. Five-week-old mice were anaesthetized
with avertin (14 ml g 1 and 250mg kg 1 intraperitoneally). Four hundred
nanograms of p24 antigen of lentiviral vectors in a ﬁnal volume of 2.5 ml encoding
for the speciﬁc transgenes depending on the experiment were stereotaxically
co-injected into the striatum in the following coordinates: anteroposterior:
þ 0.6mm, lateral: ±1.8mm, ventral: 3.3mm and tooth bar: 0.
Behaviour assays. Six-week-old mice were submitted to a battery of motor tests
starting 2 days before the beginning of the study (t¼ 0) and every 2/3 weeks until
8/9 weeks, depending on the study. All tests were performed in a dark room with,
at least, 60min of acclimatization to the experimental room and at the same period
of the day (during the morning until early afternoon). Details of each test can be
found in the Supplementary Methods.
Histology. We performed ﬂuorescent and colorimetric immunohistochemistry on
serial coronal and saggital sections spanning rostrocaudal extent of the striatum or
mediolateral extent of the cerebellum. All equivalent sections between the groups
were evaluated and treated/imaged under the same conditions. Details of the
procedure and of the quantiﬁcations can be found in the Supplementary Methods.
Immunoblotting analysis. Immunoblots were performed as described13,16 and
speciﬁc details can be found in the Supplementary Methods. Images have
been cropped for presentation. Full-size images are presented in Supplementary
Figs 6–17.
Gene expression. Total RNA were isolated using commercially available kit
(Macherey-Nagel) according to the manufacturer’s instructions. Complementary
DNA was then obtained by conversion of total RNA with iScript Selected cDNA
Synthesis kit (Bio-Rad) according to manufacturer’s instructions and stored at
 20 C. Gene expression was determined by quantitative PCR as described15.
See Supplementary Table 1 and Supplementary Methods for more details.
Engineering of shRNA. An shRNA negative (control), an shRNA targeting SIRT1
and an shRNA targeting ATG5 were created. For each one, a pair of oligonu-
cleotides was designed. The sequences of each pair of oligonucleotides can be found
in the Supplementary Experimental Procedures. Each pair of oligonucleotides were
annealed and inserted in linearized p-ENTR/pSUPERþ (AddGene 575-1). The
H1-shRNA cassette was then transferred, with LR clonase recombination system,
into SIN-cPPT-PGK-EGFP-WHV-LTR gateway destination vector. See
Supplementary Table 1 for more details.
Neuroblastoma cell culture. Mouse neuroblastoma cell line (Neuro-2a cells) was
obtained from the American Type Culture Collection cell biology bank (CCL-131)
and maintained in DMEM medium supplemented with 10% fetal bovine serum,
100Uml 1 penicillin and 100mgml 1 streptomycin (Gibco) (complete medium)
at 37 C in 5% CO2/air atmosphere. Neuro2a cell infection was performed as
previously described16. At 2 weeks post infection, cells were incubated, or not with
100 mM of chloroquine (Sigma-Aldrich) during 3 h and then were lysed for western
blot processing. In shRNA targeting ATG5/SIRT1 study, Neuro2a cells were plated
and 24 h later were transduced with respective plasmids, using polyethyleneimine
as transfection reagent. Forty-eight hours later, cells were collected and lysed for
western blot processing.
Statistical analysis. Statistical analysis was performed with paired or unpaired
Student’s t-test and one-way or two-way analysis of variance followed by the
adequate post hoc test, for multiple comparisons. Results are expressed as
mean±s.e.m. Signiﬁcant thresholds were set at Po0.05, Po0.01 and Po0.001,
as deﬁned in the text.
Additional methods. Detailed methods, including behavioural tests, histological
processing and biochemical analysis are described in Supplementary Methods.
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